He Shou Wu for Cognitive Function

The cognitive and neuroprotective effects of He Shou Wu (Polygonum multiflorum) are among the most actively studied applications in the modern preclinical literature, with the active compound 2,3,5,4'-tetrahydroxystilbene-2-O-glucoside (TSG) producing measurable effects on amyloid-β toxicity, tau hyperphosphorylation, hippocampal neurogenesis, BDNF expression, microglial inflammation, and cognitive performance in transgenic Alzheimer mouse models. The Yang et al. (2014) human trial extended the preclinical signal to a small cohort of patients with mild cognitive impairment and aging-associated memory complaints. The translational caveat is unavoidable: the strongest data are preclinical, the human trials are small, the placebo-controlled rigor is limited, and any decision to use He Shou Wu for cognitive support must weigh the benefit against the hepatotoxicity risk that the companion Liver Health and Hepatotoxicity Warning deep-dive details. This page walks through the cognitive mechanisms one by one, the key trials, the comparison with better-evidenced cognitive interventions, and the realistic role of He Shou Wu in a modern integrative cognitive-support protocol.

TSG and Anti-Alzheimer Preclinical Data
Amyloid-Beta Toxicity Reduction
Tau Hyperphosphorylation Reduction
Hippocampal Neurogenesis and BDNF Upregulation
Neuroinflammation and Microglial Phenotype
Oxidative Stress in the Aging Brain
Yang 2014 Human Cognition Trial
Comparison with Other Cognitive Interventions
Realistic Integrative Cognitive Protocol
Cautions — Cognitive Use Carries the Same Hepatic Risk
Key Research Papers
Connections

TSG and Anti-Alzheimer Preclinical Data

The 2,3,5,4'-tetrahydroxystilbene-2-O-glucoside (TSG) molecule has accumulated one of the most extensive single-compound preclinical Alzheimer's disease evidence bases of any TCM-derived isolate. The model systems range from cell culture (PC12 neuronal cells, primary hippocampal neurons, SH-SY5Y human neuroblastoma cells) through transgenic mouse models (APP/PS1, 3xTg-AD, APP23 lines that overexpress mutant human amyloid precursor protein and develop amyloid plaques) to a small number of human studies.

The consistent preclinical findings across these systems:

TSG reduces beta-amyloid-induced neurotoxicity in cell culture at micromolar concentrations
TSG reduces hippocampal amyloid plaque burden in transgenic mice given 4 to 16 weeks of oral or IP dosing
TSG reduces tau hyperphosphorylation at multiple Alzheimer-relevant epitopes (pSer202, pThr205, pSer396)
TSG improves performance on standard rodent learning and memory tasks (Morris water maze, novel object recognition, Y-maze)
TSG reduces hippocampal and cortical microglial activation, shifting microglia from the pro-inflammatory M1 phenotype toward the alternatively-activated M2 phenotype
TSG upregulates BDNF expression in the hippocampus and supports dentate-gyrus neurogenesis
TSG protects mitochondrial function in neurons exposed to amyloid-β or other toxic stressors

The mechanistic picture is that TSG is acting on multiple parallel pathways relevant to Alzheimer's pathophysiology rather than on a single target. This polypharmacology is characteristic of complex herbal compounds and is both a strength (multiple mechanisms may produce additive effect, less prone to single-pathway escape) and a weakness (harder to characterize precisely, harder to dose-optimize for a single endpoint).

The translational challenge is the same one faced by every Alzheimer preclinical signal: the mouse transgenic models reproduce some but not all features of the human disease, the dosing regimens used in mice are often not directly translatable to humans (some studies use the equivalent of grams per day in a human), and the human Alzheimer trials of compounds with strong preclinical signals (including the anti-amyloid antibodies until very recently) have a long history of disappointment.

The reasonable interpretation: TSG and He Shou Wu have a real and reproducible preclinical signal for cognitive protection and Alzheimer-relevant pathology reduction. This signal is suggestive but not yet established in humans. The strength of the preclinical evidence justifies continued investigation but does not justify positioning He Shou Wu as an established Alzheimer's prevention or treatment.

Back to Table of Contents

Amyloid-Beta Toxicity Reduction

The amyloid hypothesis of Alzheimer's disease — that abnormal aggregation of amyloid-β peptides (especially Aβ1-42) into oligomers, fibrils, and plaques drives downstream neurodegeneration — has been the dominant pathophysiologic framework for three decades. The 2021-2024 successes of anti-amyloid monoclonal antibodies (lecanemab, donanemab) in modestly slowing clinical decline in early Alzheimer's have partially validated the framework, though with safety costs (ARIA, the amyloid-related imaging abnormalities of cerebral edema and microhemorrhage).

TSG and He Shou Wu extracts have been shown to act on multiple steps of the amyloid pathway:

Reduced amyloid production — in some studies, TSG modulates the activity or expression of α-secretase (non-amyloidogenic processing of amyloid precursor protein), β-secretase (BACE1, the rate-limiting amyloidogenic step), or γ-secretase, shifting APP processing away from the amyloidogenic pathway.
Reduced amyloid aggregation — cell-culture studies show TSG can disrupt the secondary nucleation of amyloid oligomers, an effect shared with resveratrol and several other stilbene compounds.
Reduced amyloid-induced neurotoxicity — when neurons are co-incubated with pre-formed amyloid-β oligomers (which are the most toxic species), TSG pre-treatment reduces the resulting calcium influx, mitochondrial dysfunction, and apoptosis.
Enhanced amyloid clearance — some studies suggest TSG supports microglial phagocytosis of amyloid plaques in transgenic mouse models, contributing to reduced amyloid burden in chronically treated animals.
Reduced amyloid plaque deposition in vivo — the integrated effect in APP/PS1 transgenic mice given 8 to 16 weeks of TSG is a 20 to 40% reduction in hippocampal and cortical amyloid plaque burden compared to vehicle-treated transgenic controls.

The magnitude of these effects in mice is comparable to what some early-development anti-amyloid drugs achieve, and notable in that TSG is achieving the effect without the ARIA safety signal that has limited the antibody drugs. The caveat is that mouse plaque models do not always predict human clinical efficacy.

Back to Table of Contents

Tau Hyperphosphorylation Reduction

The tau pathology of Alzheimer's disease — hyperphosphorylation of the microtubule-associated tau protein leading to its detachment from microtubules, aggregation into paired helical filaments, and formation of neurofibrillary tangles — correlates more strongly with cognitive decline than amyloid plaque burden in many human studies. Tau-targeted therapies are an active area of drug development, and the preclinical evidence for TSG and tau is among the more interesting parts of the He Shou Wu cognitive literature.

TSG has been shown to:

Reduce phosphorylation of tau at multiple Alzheimer-relevant epitopes including pSer202, pThr205, pSer396, and pSer404
Modulate the activity of the kinases that phosphorylate tau (most importantly GSK-3β, but also CDK5 and the MAPK family)
Support the activity of PP2A (protein phosphatase 2A), the principal phosphatase that dephosphorylates tau and whose activity is decreased in Alzheimer brain
Reduce tau aggregation in cell-culture models of toxic tau species
Reduce neurofibrillary-tangle-like pathology in tau-transgenic mouse models

The GSK-3β effect is mechanistically the most interesting because GSK-3β is also implicated in mood disorders (lithium's antidepressant effect is partially attributed to GSK-3β inhibition) and in insulin signaling (GSK-3β is downstream of insulin receptor signaling, contributing to the "Type 3 diabetes" framing of Alzheimer's as a brain insulin-resistance condition). TSG's GSK-3β effect connects the cognitive benefits to the broader metabolic and inflammatory effects covered in the Longevity and Cardiovascular deep-dive.

Back to Table of Contents

Hippocampal Neurogenesis and BDNF Upregulation

The adult mammalian hippocampus retains the capacity for neurogenesis — new neurons are generated from neural stem cells in the subgranular zone of the dentate gyrus throughout adult life, though the rate declines with age and is dramatically reduced in Alzheimer's disease and in chronic stress / depression. Restoring or enhancing hippocampal neurogenesis is a target of several emerging cognitive interventions.

TSG has been shown in rodent models to:

Increase the proliferation of neural progenitor cells in the dentate gyrus subgranular zone (measured by BrdU incorporation or Ki-67 staining)
Increase the survival and maturation of newborn neurons over the 3 to 4 weeks required for full integration into hippocampal circuits
Upregulate BDNF (brain-derived neurotrophic factor) expression in the hippocampus, dentate gyrus, and cortex
Upregulate TrkB (the BDNF receptor) signaling, including phosphorylation of TrkB and downstream Akt/CREB
Upregulate other neurotrophic factors including NGF (nerve growth factor) and GDNF (glial-derived neurotrophic factor) in some studies

BDNF is one of the most extensively characterized molecules in cognitive neuroscience. It is required for long-term potentiation (LTP, the cellular correlate of learning and memory), for hippocampal-dependent memory consolidation, for the maturation and survival of new neurons, and for synaptic plasticity in adult cortex. BDNF expression is downregulated in depression, in chronic stress, in obesity, in metabolic syndrome, and in Alzheimer's disease. Interventions that upregulate BDNF — including aerobic exercise (the strongest known BDNF inducer), intermittent fasting, sleep, several antidepressants (the SSRI/SNRI class), and a growing number of natural compounds — tend to support cognitive function and mood.

TSG's BDNF effect places it in this BDNF-upregulating compound class, which also includes bacopa monnieri, lion's mane, curcumin, omega-3 fatty acids (EPA in particular), and several flavonoids. The realistic clinical interpretation is that TSG is one of many possible levers for BDNF support, not a uniquely potent one.

For broader context on cognitive support, see our pages on Bacopa Monnieri, Ginkgo Biloba, and the Alzheimer's Disease page.

Back to Table of Contents

Neuroinflammation and Microglial Phenotype

Chronic neuroinflammation — sustained low-grade activation of microglia and astrocytes, with elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and activation of NF-κB signaling — is now recognized as a central feature of Alzheimer's disease and probably a causal contributor rather than just a downstream response. The TREM2 gene, identified through Alzheimer GWAS, codes for a microglial receptor; loss-of-function variants substantially increase Alzheimer risk and lock in this neuroinflammatory framework.

TSG and He Shou Wu extracts have well-characterized anti-neuroinflammatory effects:

NF-κB suppression — TSG reduces nuclear translocation of NF-κB in LPS-stimulated microglia, dampening the master pro-inflammatory transcription program
Microglial M1-to-M2 phenotype shift — microglia exist along a spectrum from classically-activated pro-inflammatory M1 (producing IL-1β, TNF-α, iNOS) to alternatively-activated reparative M2 (producing IL-10, arginase, growth factors). Aging and neurodegeneration shift the population toward M1; TSG shifts it back toward M2.
Reduced cytokine cascade — IL-1β, IL-6, TNF-α, and downstream COX-2 and iNOS expression are reduced in TSG-treated tissue
NLRP3 inflammasome suppression — the NLRP3 inflammasome is a key innate-immune complex activated by amyloid-β oligomers, and its activation drives IL-1β maturation. Some TSG studies report direct NLRP3 inhibition.
BBB stabilization — some evidence that TSG supports blood-brain barrier integrity, which is disrupted in early Alzheimer's and contributes to neuroinflammatory injury

The anti-neuroinflammatory mechanism is shared with several other neuroprotective natural compounds (curcumin, resveratrol, EGCG, omega-3 EPA) and represents one of the more therapeutically interesting modes of action because it acts on a process that is causally upstream of both amyloid and tau pathology in some models.

Back to Table of Contents

Oxidative Stress in the Aging Brain

The brain is one of the organs most vulnerable to oxidative damage because of its high metabolic rate (the brain consumes approximately 20% of total body oxygen despite being 2% of body mass), high polyunsaturated fatty acid content in neuronal membranes (susceptible to lipid peroxidation), and relatively low endogenous antioxidant capacity (catalase is low in brain compared to liver). Cumulative oxidative damage to neurons, mitochondria, and DNA is implicated in the aging process and in several neurodegenerative diseases.

The TSG and broader stilbene-family antioxidant effects translate to brain tissue:

Direct ROS quenching (similar to resveratrol)
Upregulation of endogenous antioxidant enzymes: superoxide dismutase (SOD, both Cu/Zn and Mn forms), glutathione peroxidase (GPx), catalase
Upregulation of glutathione synthesis through Nrf2 pathway activation
Mitochondrial protection: TSG reduces mitochondrial membrane permeabilization, preserves Complex I and IV activity, and reduces ROS generation at Complex III in stressed neurons
Reduced lipid peroxidation (measured as MDA, malondialdehyde) in brain tissue from TSG-treated animals
Reduced 8-OHdG (oxidative DNA damage marker) in brain tissue

The Nrf2 pathway is mechanistically central here. Nrf2 (nuclear factor erythroid 2-related factor 2) is the master transcription factor for cellular antioxidant response. Under basal conditions, Nrf2 is sequestered in the cytoplasm by Keap1; under oxidative or electrophilic stress, Nrf2 translocates to the nucleus and induces dozens of antioxidant and detoxification genes (HO-1, NQO1, glutamate-cysteine ligase, glutathione synthase). TSG has been shown to activate the Nrf2 pathway in neuronal cell culture and in vivo, an effect shared with sulforaphane, curcumin, and several other neuroprotective natural compounds.

For more on oxidative stress and antioxidant biology, see our Oxidative Stress page.

Back to Table of Contents

Yang 2014 Human Cognition Trial

The most-cited human cognitive trial of Polygonum multiflorum is Yang et al. (2014), which evaluated a standardized extract in patients with mild cognitive impairment (MCI) and aging-associated memory complaints. The trial design and findings:

Open-label cohort design (a methodological limitation — not placebo-controlled, not blinded)
Participants: adults with subjective memory complaints and objective cognitive testing in the MCI range, typically mid-60s to mid-70s age
Intervention: standardized Polygonum multiflorum processed-root extract, daily for 12 to 24 weeks
Outcomes: standardized cognitive testing batteries (MMSE, MoCA, supplementary memory and executive-function tasks) at baseline, mid-treatment, and end-treatment
Findings: measurable improvement on memory and executive-function subscales at end of treatment; magnitude was modest (a few points on the cognitive batteries)
Safety: LFT monitoring was included; no clinically significant hepatic events reported in this cohort, though the sample size was too small to detect rare events

The methodological limitations — open-label, no placebo, small sample, short duration relative to the slow trajectory of cognitive decline — mean that the trial cannot be considered definitive evidence of cognitive benefit. The result is consistent with the preclinical mechanistic data but does not establish efficacy at the level of evidence required for treatment recommendations.

Subsequent smaller open-label trials and case series from Chinese clinical centers have generally reported directionally similar findings — modest improvement on cognitive testing batteries in older adults with subjective or mild objective cognitive impairment, with the processed root form, over treatment courses of 12 to 24 weeks. A rigorous double-blind placebo-controlled trial of TSG monotherapy or standardized Polygonum multiflorum extract in MCI populations would be welcome and is not yet available in the English-language literature.

Back to Table of Contents

Comparison with Other Cognitive Interventions

Where does He Shou Wu fit in the broader landscape of cognitive interventions? Honest comparison requires acknowledging that the evidence base for He Shou Wu is preclinical-heavy, while the evidence base for several alternatives is human-trial-heavier. Relative position:

Aerobic exercise — the single most evidence-supported cognitive intervention. Slows hippocampal atrophy in older adults, increases hippocampal BDNF, improves multiple cognitive domains. He Shou Wu is not a substitute for exercise.
Mediterranean / MIND diet — strong observational and some interventional evidence for reduced Alzheimer's risk. Should be the dietary foundation.
Sleep optimization — deep sleep is the period of glymphatic clearance of amyloid-β from the brain. Chronic sleep restriction is a major modifiable risk factor.
Hearing aids for hearing loss — the ACHIEVE trial showed that addressing hearing loss in older adults slows cognitive decline. Possibly the largest-effect single modifiable intervention.
Cardiovascular risk management — blood pressure control, lipid management, diabetes management, smoking cessation. The cardiovascular and Alzheimer risk factors overlap heavily.
Omega-3 EPA/DHA — moderate evidence for cognitive support, particularly in those with low baseline omega-3 status. See Omega-3 Fatty Acids.
Vitamin D — observational association with cognitive function; interventional evidence is mixed. See Vitamin D3.
B vitamin complex — B12, folate, B6 lower homocysteine, which is associated with cognitive decline. Particularly relevant in older adults with subclinical B12 deficiency. See Vitamin B12.
Bacopa monnieri — modest evidence for memory improvement in healthy older adults; reasonable better-evidenced alternative to He Shou Wu for cognitive use. See Bacopa Monnieri.
Lion's mane mushroom — NGF-stimulating effect with some small human cognitive data. See Lion's Mane.
Ginkgo biloba — mixed evidence; modest effect at best. See Ginkgo Biloba.
He Shou Wu — mechanistically promising, preclinical evidence is strong, human evidence is limited and methodologically weak, hepatotoxicity risk is real. Best positioned as a niche option for individuals who have addressed the higher-evidence interventions and want to add a TCM tonic with awareness of the safety profile.
FDA-approved Alzheimer drugs — donepezil, rivastigmine, memantine for symptomatic management; lecanemab and donanemab for early disease with confirmed amyloid pathology. These are the only interventions with established disease-modifying efficacy in confirmed Alzheimer's, though with their own safety considerations.

The honest summary: if cognitive support is the goal, prioritize the high-evidence interventions first. He Shou Wu is a reasonable addition for those who want a TCM-tradition component, who have addressed the foundations, who do not have the absolute contraindications, and who are committed to the hepatic monitoring protocol.

Back to Table of Contents

Realistic Integrative Cognitive Protocol

A reasonable integrative cognitive-support protocol layering He Shou Wu with the higher-evidence components, for an adult in their 60s or 70s with subjective memory complaints and mild objective cognitive testing decline:

Address modifiable cardiovascular risk — blood pressure, lipids, diabetes, smoking, weight, sleep apnea
Aerobic exercise — 150+ minutes per week of moderate-intensity, plus 2 sessions of resistance training
Mediterranean-style diet — emphasizing fish, leafy greens, olive oil, nuts, berries; reducing ultra-processed foods, refined carbohydrate, and excess alcohol
Sleep optimization — 7-8 hours, address sleep apnea if present, evaluate for restless legs syndrome
Address sensory deficits — hearing test and hearing aids if indicated, vision check
Nutrient repletion — check and optimize B12, folate, vitamin D, omega-3 index, iron, thyroid
Cognitive engagement — novel learning, social interaction, complex tasks (language learning, music, complex hobbies)
Consider He Shou Wu — only after the above are in place and with full understanding of the hepatic risk and monitoring requirements. Processed root, 1 to 2 g standardized extract daily, 12 weeks on / 4 weeks off, with baseline and 4-week / 12-week LFTs.
Adjacent better-evidenced cognitive herbs — Bacopa monnieri 300 mg daily of standardized extract, lion's mane mushroom 1-3 g daily, with much lower hepatotoxicity concern
Regular cognitive testing — baseline and annual cognitive screening to track trajectory
Specialist referral — neurology / geriatrics if objective decline progresses

The cognitive use of He Shou Wu carries the same hepatic risk profile as the hair-tonic use — do not assume that "lower dose" or "different indication" reduces the idiosyncratic immune-mediated injury risk. The full hepatotoxicity warning applies.

Back to Table of Contents

Cautions — Cognitive Use Carries the Same Hepatic Risk

Hepatotoxicity — the dominant safety issue, identical to other indications. See the dedicated Liver Health and Hepatotoxicity Warning deep-dive for the full protocol.
Drug interactions in the elderly — the cognitive-support population is often on multiple medications. Statins, anticoagulants, antihypertensives, antidepressants, and anti-dementia drugs (donepezil, rivastigmine, memantine) all warrant review before adding He Shou Wu.
Falls risk — not a known He Shou Wu effect specifically, but any cognitively impaired older adult on a new medication or supplement should be reassessed for fall risk and medication interactions that could affect alertness.
Cognitive enhancement claims in healthy young adults — the cognitive evidence base is in older adults with cognitive impairment. There is no evidence to support He Shou Wu as a "nootropic" for cognitively-intact young adults, and the hepatotoxicity risk in that population is unjustified by the absence of clear benefit.
Use with anti-amyloid antibody therapy — the new anti-amyloid antibodies (lecanemab, donanemab) have their own monitoring requirements (MRI for ARIA). Adding He Shou Wu with additional LFT monitoring requirements creates a complex supervision picture that should be discussed with the prescribing neurologist.
Quality matters — for cognitive use, use only TSG-standardized extracts from reputable manufacturers with third-party testing, not bulk powders

Back to Table of Contents

Key Research Papers

Yang JJ et al. (2014). Cognitive effects of Polygonum multiflorum in mild cognitive impairment and aging-associated memory. — PubMed
Wang T et al. (2007). 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside attenuates Alzheimer-like pathology in APP/PS1 transgenic mice. — PubMed
Zhang L et al. (2012). 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside protects PC12 cells against beta-amyloid-induced cell death. — PubMed
Chen Y et al. (2013). TSG reduces tau hyperphosphorylation through GSK-3β modulation. — PubMed
Liu Q et al. (2015). Stilbene glycoside from Polygonum multiflorum upregulates BDNF and hippocampal neurogenesis. — PubMed
Hu Y et al. (2017). TSG suppresses NF-κB and microglial activation in transgenic Alzheimer models. — PubMed
Zhang ZH et al. (2014). Polygonum multiflorum stilbene glycoside protects against amyloid-β via Nrf2 pathway. — PubMed
Lv L et al. (2012). Cognitive enhancement of TSG in scopolamine-impaired memory mouse model. — PubMed
Lin EJ et al. (2013). The Wnt/β-catenin pathway in adult hippocampal neurogenesis. Frontiers in Neuroscience. — PubMed
Sun FL et al. (2013). TSG attenuates oxidative stress in primary cortical neurons through Nrf2-HO-1 pathway. — PubMed
Livingston G et al. (2024). Dementia prevention, intervention, and care: 2024 Lancet Commission report. — PubMed
Hong YL et al. (2017). Pharmacokinetics of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside (TSG) in rats and humans. — PubMed

PubMed Topic Searches

Back to Table of Contents

Connections

Back to Table of Contents